Grassy G, Calas B, Yasri A, Lahana R, Woo J, Iyer S, Kaczorek M, Floc'h R, Buelow R
Centre de Biochimie Structurale, UMR CNRS 9955, INSERM U414, Faculté de Pharmacie, Montpellier, France.
Nat Biotechnol. 1998 Aug;16(8):748-52. doi: 10.1038/nbt0898-748.
We describe the rational design of immunosuppressive peptides without relying on information regarding their receptors or mechanisms of action. The design strategy uses a variety of topological and shape descriptors in combination with an analysis of molecular dynamics trajectories for the identification of potential drug candidates. This strategy was applied to the development of immunosuppressive peptides with enhanced potency. The lead compounds were peptides, derived from the heavy chain of HLA class I, that modulate immune responses in vitro and in vivo. In particular, a peptide derived from HLA-B2702, amino acids 75-84 (2702.75-84) prolonged skin and heart allograft survival in mice. The biological activity of the rationally designed peptides was tested in a heterotopic mouse heart allograft model. The molecule predicted to be most potent displayed an immunosuppressive activity approximately 100 times higher than the lead compound.
我们描述了不依赖免疫抑制肽受体信息或作用机制的合理设计方法。该设计策略结合使用多种拓扑和形状描述符,并分析分子动力学轨迹以识别潜在的候选药物。此策略被应用于开发效力增强的免疫抑制肽。先导化合物是源自HLA I类重链的肽,其在体外和体内均能调节免疫反应。特别是,一种源自HLA - B2702(氨基酸75 - 84,即2702.75 - 84)的肽延长了小鼠皮肤和心脏同种异体移植物的存活时间。在异位小鼠心脏同种异体移植模型中测试了合理设计肽的生物活性。预测最有效的分子显示出的免疫抑制活性比先导化合物高约100倍。